Ann: Comment on research report, page-93

the target is Acadia and unfortunately NEU is the collateral damage. Acadia share price only dropped by 1.5% so they were not that successful at bringing down the SP. You would think that ACADIA would come out with some sort of statement tonight but Jon does not think so for whatever reason. I guess if Acadia share price continues to hold up, they would not need to comment on it as the market has spoken

Neuren chief executive Jon Pilcher told The Australian that responding to the finer points of the report was for Acadia to contemplate, and reiterated that both Neuren and Acadia were widely covered by analysts, who themselves had surveyed physicians prescribing the drug, who “all come to a different view’’.He also made the point that the Acadia share price closed up in US trade overnight, reflecting the weight investors were placing on the report. He said he did not expect Acadia to respond directly to the claims.